我們已在上線！進一步了解

Evolent Health

EVH

市值 US$5.17億

4.57 USD

-0.30

6.16%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

4.57

0.00

0%

1天

-6.16%

5天

13.12%

1個月

22.19%

3個月

-19.4%

6個月

52.84%

今年迄今

17.48%

1年

-41.41%

5年

-84.98%

10年

-79.91%

關於： Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.

員工： 4,200

醫療保健健康資訊服務

新聞

正面

中性

負面

市場情緒 3個月

正面 44.4%

中性 55.6%

負面 0%

Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026

WASHINGTON, Oct. 9, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its third quarter 2026 financial results on Thursday, November 5, 2026, before market open, with a conference call to follow at 8:30 a.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.

Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026

TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation

TransPerfect expands its Evolent partnership to provide enterprise-wide telephonic interpretation and strengthen language access for health plan members.

TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation

Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming

Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term debt and persistent GAAP losses. Management projects >25% revenue growth and adjusted EBITDA ≥$150m in 2027, aiming to improve leverage and capital structure.

Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming

Evolent Health Q2 Earnings Call Highlights

Evolent Health NYSE: EVH reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially, as the company benefited from the May launch of its Highmark partnership and continued growth in its Performance Suite business.

Evolent Health Q2 Earnings Call Highlights

Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript

Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript

Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research

Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates

Evolent Health (EVH) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.1 per share a year ago.

Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates

Evolent Announces Second Quarter 2026 Results

WASHINGTON, Aug. 6, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2026. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow.

Evolent Announces Second Quarter 2026 Results

Forget Nvidia. These 5 S&P 500 stocks are quietly going all in on AI.

The “Mag Seven” has become the “Bag Seven.” Sharp tech investors are looking elsewhere.

Forget Nvidia. These 5 S&P 500 stocks are quietly going all in on AI.

Zacks Investment Research

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now

Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now

查看新聞排名

價格圖表採用Lightweight Charts™實作